129 related articles for article (PubMed ID: 27446558)
1. Cetuximab for the treatment of locally advanced and recurrent/metastatic oral cancer: An investigation of distant metastasis.
Naruse T; Yanamoto S; Matsushita Y; Sakamoto Y; Morishita K; Ohba S; Shiraishi T; Yamada SI; Asahina I; Umeda M
Mol Clin Oncol; 2016 Aug; 5(2):246-252. PubMed ID: 27446558
[TBL] [Abstract][Full Text] [Related]
2. [Cetuximab in head and neck squamous cell carcinoma: a systematic review and Meta-analysis].
Song Q; Li X; Li B
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2015 Jan; 29(1):67-75. PubMed ID: 25966559
[TBL] [Abstract][Full Text] [Related]
3. Final Results of a Randomized Phase 2 Trial Investigating the Addition of Cetuximab to Induction Chemotherapy and Accelerated or Hyperfractionated Chemoradiation for Locoregionally Advanced Head and Neck Cancer.
Seiwert TY; Melotek JM; Blair EA; Stenson KM; Salama JK; Witt ME; Brisson RJ; Chawla A; Dekker A; Lingen MW; Kocherginsky M; Villaflor VM; Cohen EE; Haraf DJ; Vokes EE
Int J Radiat Oncol Biol Phys; 2016 Sep; 96(1):21-9. PubMed ID: 27511844
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and Tolerance of Cetuximab Alone or Combined with Chemotherapy in Locally Advanced or Metastatic Cutaneous Squamous Cell Carcinoma: An Open Study of 14 Patients.
Dereure O; Missan H; Girard C; Costes V; Guillot B
Dermatology; 2016; 232(6):721-730. PubMed ID: 28384639
[TBL] [Abstract][Full Text] [Related]
5. Multicenter phase II study of combination therapy with cetuximab and S-1 in patients with KRAS exon 2 wild-type unresectable colorectal cancer previously treated with irinotecan, oxaliplatin, and fluoropyrimidines (KSCC 0901 study).
Takahashi T; Emi Y; Oki E; Kobayashi K; Tsuji A; Shimokawa M; Tanaka T; Akagi Y; Ogata Y; Baba H; Yoshida K; Natsugoe S; Maehara Y;
Cancer Chemother Pharmacol; 2016 Sep; 78(3):585-93. PubMed ID: 27468920
[TBL] [Abstract][Full Text] [Related]
6. Phase II trial of combination treatment with paclitaxel, carboplatin and cetuximab (PCE) as first-line treatment in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (CSPOR-HN02).
Tahara M; Kiyota N; Yokota T; Hasegawa Y; Muro K; Takahashi S; Onoe T; Homma A; Taguchi J; Suzuki M; Minato K; Yane K; Ueda S; Hara H; Saijo K; Yamanaka T
Ann Oncol; 2018 Apr; 29(4):1004-1009. PubMed ID: 29408977
[TBL] [Abstract][Full Text] [Related]
7. [Efficacy of cetuximab combined with chemotherapy for patients with advanced colorectal cancer and unclear K-ras status].
Guo GF; Xia LP; Qiu HJ; Xu RH; Zhang B; Jiang WQ; Zhou FF; Wang F
Zhonghua Zhong Liu Za Zhi; 2010 Oct; 32(10):777-81. PubMed ID: 21163071
[TBL] [Abstract][Full Text] [Related]
8. Docetaxel plus cetuximab biweekly is an active regimen for the first-line treatment of patients with recurrent/metastatic head and neck cancer.
Posch D; Fuchs H; Kornek G; Grah A; Pammer J; Aretin MB; Fuereder T
Sci Rep; 2016 Sep; 6():32946. PubMed ID: 27597175
[TBL] [Abstract][Full Text] [Related]
9. Cetuximab in combination with chemoradiotherapy in Chinese patients with non-resectable, locally advanced esophageal squamous cell carcinoma: a prospective, multicenter phase II trail.
Meng X; Wang J; Sun X; Wang L; Ye M; Feng P; Zhu G; Lu Y; Han C; Zhu S; Liao Z; Yu J
Radiother Oncol; 2013 Nov; 109(2):275-80. PubMed ID: 24128808
[TBL] [Abstract][Full Text] [Related]
10. Randomized phase II trial of cixutumumab alone or with cetuximab for refractory recurrent/metastatic head and neck squamous cell carcinoma.
Ferrarotto R; William WN; Tseng JE; Marur S; Shin DM; Murphy B; Cohen EEW; Thomas CY; Willey R; Cosaert J; Harun N; Jack Lee J; Wistuba IW; Haddad RI; Glisson BS
Oral Oncol; 2018 Jul; 82():83-90. PubMed ID: 29909907
[TBL] [Abstract][Full Text] [Related]
11. Systematic review and economic evaluation of bevacizumab and cetuximab for the treatment of metastatic colorectal cancer.
Tappenden P; Jones R; Paisley S; Carroll C
Health Technol Assess; 2007 Mar; 11(12):1-128, iii-iv. PubMed ID: 17346499
[TBL] [Abstract][Full Text] [Related]
12. Multicenter retrospective study of cetuximab plus platinum-based chemotherapy for recurrent or metastatic oral squamous cell carcinoma.
Yanamoto S; Umeda M; Kioi M; Kirita T; Yamashita T; Hiratsuka H; Yokoo S; Tanzawa H; Uzawa N; Shibahara T; Ota Y; Kurita H; Okura M; Hamakawa H; Kusukawa J; Tohnai I
Cancer Chemother Pharmacol; 2018 Mar; 81(3):549-554. PubMed ID: 29383483
[TBL] [Abstract][Full Text] [Related]
13. Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial.
Lordick F; Kang YK; Chung HC; Salman P; Oh SC; Bodoky G; Kurteva G; Volovat C; Moiseyenko VM; Gorbunova V; Park JO; Sawaki A; Celik I; Götte H; Melezínková H; Moehler M;
Lancet Oncol; 2013 May; 14(6):490-9. PubMed ID: 23594786
[TBL] [Abstract][Full Text] [Related]
14. Effect of Adding Motolimod to Standard Combination Chemotherapy and Cetuximab Treatment of Patients With Squamous Cell Carcinoma of the Head and Neck: The Active8 Randomized Clinical Trial.
Ferris RL; Saba NF; Gitlitz BJ; Haddad R; Sukari A; Neupane P; Morris JC; Misiukiewicz K; Bauman JE; Fenton M; Jimeno A; Adkins DR; Schneider CJ; Sacco AG; Shirai K; Bowles DW; Gibson M; Nwizu T; Gottardo R; Manjarrez KL; Dietsch GN; Bryan JK; Hershberg RM; Cohen EEW
JAMA Oncol; 2018 Nov; 4(11):1583-1588. PubMed ID: 29931076
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of weekly paclitaxel combined with cetuximab in the treatment of pretreated recurrent/metastatic head and neck cancer patients.
Jiménez B; Trigo JM; Pajares BI; Sáez MI; Quero C; Navarro V; Llácer C; Medina L; Rueda A; Alba E
Oral Oncol; 2013 Feb; 49(2):182-5. PubMed ID: 23026069
[TBL] [Abstract][Full Text] [Related]
16. Cetuximab Plus irinotecan in pretreated metastatic colorectal cancer progressing on irinotecan: the LABEL study.
Buzaid AC; Mathias Cde C; Perazzo F; Simon SD; Fein L; Hidalgo J; Murad AM; Esser R; Senger S; Lerzo G
Clin Colorectal Cancer; 2010 Dec; 9(5):282-9. PubMed ID: 21208842
[TBL] [Abstract][Full Text] [Related]
17. Phase 2 study of concurrent cetuximab plus definitive thoracic radiation therapy followed by consolidation docetaxel plus cetuximab in poor prognosis or elderly patients with locally advanced non-small cell lung cancer.
Dilling TJ; Extermann M; Kim J; Thompson LM; Yue B; Stevens CW; Antonia S; Gray J; Williams C; Haura E; Pinder-Schenck M; Tanvetyanon T; Kim S; Chiappori A
Int J Radiat Oncol Biol Phys; 2014 Nov; 90(4):828-33. PubMed ID: 25216856
[TBL] [Abstract][Full Text] [Related]
18. Predictive Value of Cetuximab-Induced Skin Toxicity in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and NECK.
Uozumi S; Enokida T; Suzuki S; Nishizawa A; Kamata H; Okano T; Fujisawa T; Ueda Y; Okano S; Tahara M; Yamaguchi M
Front Oncol; 2018; 8():616. PubMed ID: 30619755
[No Abstract] [Full Text] [Related]
19. Cetuximab-based therapy versus non-cetuximab therapy for advanced cancer: a meta-analysis of 17 randomized controlled trials.
Liu L; Cao Y; Tan A; Liao C; Gao F
Cancer Chemother Pharmacol; 2010 Apr; 65(5):849-61. PubMed ID: 19680654
[TBL] [Abstract][Full Text] [Related]
20. Intravenous 5-Fluorouracil in Patients With Advanced Squamous Cell Carcinoma: A Retrospective Study.
Buxó E; Sosa A; Reig O; Victoria I; Caballero M; Grau JJ; Garcia-Morillo M
Ann Otol Rhinol Laryngol; 2018 Jul; 127(7):456-462. PubMed ID: 29852745
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]